

Press Release

Lund, Sweden, October 14, 2024

ImmuneBiotech Medical Sweden AB Strengthens Leadership with Strategic Appointment of Rickard Mosell as Chairman of the Board

ImmuneBiotech, a pioneering probiotic and microbiome company, is pleased to announce the appointment of life science veteran Rickard Mosell as its new Chairman of the Board. This pivotal recruitment marks a major milestone in the company's growth strategy, reinforcing its leadership team.

Mr. Mosell brings a wealth of experience, having held senior leadership positions in startups, science parks, and drug development companies. His proven track record in transforming scientific innovations into scalable businesses, combined with his in-depth knowledge of the microbiome space, aligns perfectly with ImmuneBiotech's mission and will be valuable in shaping the company's strategic direction and future growth.

"We are thrilled to welcome Rickard as our new Chairman of the Board", says Shahram Lavasani, founder and CEO of ImmuneBiotech. "His extensive expertise in scaling life science businesses and his vast network within the industry and academia will be instrumental as we continue to drive our growth and expand our product offerings."

Mr. Mosell's appointment reflects ImmuneBiotech's ongoing commitment to enhancing its strategic capabilities and reinforcing its leadership in the rapidly growing probiotics and microbiome sectors. His insights will support the company's mission to deliver scientifically-backed, high-quality products that improve the lives of customers around the world.

"I am excited to join ImmuneBiotech at such an exciting time", says Rickard Mosell. "The company's commitment to innovation and human health aligns with my expectations that this field will grow strongly in the near future, and its transformative solutions in the life science industry will conquer new markets. I am eager to contribute to ImmuneBiotech's continued success as we push the boundaries of microbiome-based solutions and tap into new market opportunities."

This strategic recruitment highlights ImmuneBiotech's commitment to expanding its impact in the microbiome industry by developing and marketing science-backed probiotic products.

About ImmuneBiotech AB

ImmuneBiotech Medical Sweden AB stands at the forefront of the probiotic and microbiome sector, committed to enhancing human health and wellbeing with cutting-edge solutions. The company is developing and marketing precision-designed probiotic products, specifically targeting gastrointestinal and neurological conditions. Leveraging two decades of groundbreaking research, ImmuneBiotech has gained profound insights into the intricate



interplay among the microbiome, immune system, and intestinal barrier, leading to the creation of the innovative probiotic category, ImmuneBiotics®.

With an unwavering commitment to excellence, research, and customer satisfaction, ImmuneBiotech aims to lead the rapidly evolving probiotics and microbiome industry.

GutMagnific®: Precision Probiotic Revolutionizing Human Health

GutMagnific stands as the flagship product in the ImmuneBiotics range, representing the essence of Precision Probiotics. It is specifically created for the effective management of gastrointestinal conditions. This scientifically-developed, multi-strain, patented probiotic food/nutritional supplement is designed to foster a health balance among the microbiome, immune system, and intestinal barrier. Remarkably, beyond gastrointestinal wellness, GutMagnific has shown significant clinical efficacy in neurological conditions, thereby addressing gut-brain axis issues.

Undergoing rigorous evaluation in a randomized, blinded, placebo controlled clinical study in collaboration with Karolinska Institute in Stockholm, Sweden, GutMagnific has demonstrated significant relief from both neurological and IBS symptoms in patients with myalgic encephalomyelitis (ME) also known as chronic fatigue syndrome (CFS). GutMagnific's potential extends to several critical and widespread conditions with high unmet medical needs, such constipation, abdominal pain, antibiotic induced diarrhea, and *Clostridium difficile* infection. It is also effective in targeting symptoms related to leaky gut and small intestine bacterial overgrowth (SIBO).

The distinctive clinical and health benefits of GutMagnific underscore ImmuneBiotech's robust R&D platform, which applies pharmaceutical principles to achieve multi-targeted effects.

GutMagnific is available for purchase through company's web-shop www.GutMagnific.com.

For further information, please contact:

Shahram Lavasani, CEO

ImmuneBiotech Medical Sweden AB

s.lavasani@immunebiotech.com

+46 700 90 8946

www.ImmuneBiotech.com